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S U M M A R Y
Background: The concurrent use of nevirapine-based antiretroviral therapy (ART) and rifampin-
containing anti-tuberculosis regimens for the treatment of HIV and tuberculosis (TB) is common in
resource-limited countries. Long-term outcomes of this concurrent treatment are unknown.
Methods: Seventy HIV-infected patients receiving rifampin for active TB (TB group) and 70 HIV-mono-
infected patients (control group) were enrolled to receive nevirapine 400 mg/day-based ART. All were
followed through 4 years of ART. Plasma HIV-1 RNA and CD4 cell counts were monitored every 12 weeks
until 96 weeks, and every 24 weeks thereafter.
Results: Of the 140 patients, the median (interquartile range (IQR)) CD4 count was 31 (14–79) cells/mm3
and median (IQR) plasma HIV-1 RNA was 5.6 (5.2–5.9) log copies/ml at baseline . Thirty-nine (55.7%)
patients in the TB group were diagnosed with extrapulmonary/disseminated TB. The median duration of
concurrent administration of nevirapine and rifampin was 5.4 (4.6–6.1) months. By intention-to-treat
analysis, the percentage of patients who achieved HIV-1 RNA <50 copies/ml was 52.9% in the TB group
and 50% in control group (p = 0.866; odds ratio 1.121, 95% conﬁdence interval 0.578–2.176); median
(IQR) CD4 counts were 352 (271–580) cells/mm3 and 425 (308–615) cells/mm3 in the corresponding
groups (p = 0.238). The proportion of ART discontinuation due to any reason at 1, 2, 3, and 4 years was
21%, 34%, 37%, and 46% in the TB group and 21%, 36%, 43%, and 49% in the control group, respectively
(p = 0.651). The 4-year mortality rate was 6.4% in both groups.
Conclusions: Nevirapine-based ART is an option for HIV-infected patients who receive rifampin in
resource-limited countries or those who cannot tolerate efavirenz.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journa l homepage: www.e lsev ier .com/ locate / i j id1. Introduction
The concomitant use of antiretroviral therapy (ART) and anti-
tuberculosis therapy is associated with a reduction in mortality in
patients who are co-infected with HIV and tuberculosis (TB).1–3
Nevertheless, treatment with antiretroviral drugs in this setting is
relatively complex and requires expertise in the management of
bothHIV disease and TB.Many concerns have been raised, including
overlapping toxicities, drug–drug interactions, high pill burden
contributing to adherence challenge, and immune reconstitution
inﬂammatory syndrome.4,5 Careful attention is needed on the issue§ Presented in part as an abstract at the18th International AIDS Conference,
Vienna, Austria, 2010.
* Corresponding author. Tel.: +66 2 5903408; fax: +66 2 5903411.
E-mail address: drweerawat@hotmail.com (W. Manosuthi).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.06.016of drug–drug interactions between anti-TB drugs, antiretroviral
drugs, and other concurrent therapies. A particular concern is the
interaction of rifamycins, especially rifampin, with antiretroviral
drugs, since rifampin is a strong cytochrome P450 inducer that
results in reduction of plasma concentrations of protease inhibitors
(PI) and non-nucleoside reverse transcriptase inhibitors (NNRTI).6
Although rifabutin has fewer problematic drug–drug interactions, it
is not available in many countries, particularly not in resource-
limited settings. However, rifamycin-containing regimens are
preferred in the treatment of HIV and TB co-infection as they result
in a lower relapse rate and better outcome.7
According to current HIV treatment guidelines, including Thai
guidelines, efavirenz-based ART is a preferred ﬁrst-line regimen in
HIV/TB co-infected patients who are receiving a rifampin-contain-
ing regimen, because of the lesser drug–drug interactions when
compared to nevirapine or PIs.8 Previous studies have demon-
strated that plasma nevirapine levels are reduced by rifampin;ses. Published by Elsevier Ltd. All rights reserved.
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tic nevirapine levels.9–12 Furthermore, the short-term data on
virological response among patients concurrently receiving
nevirapine and rifampin are acceptable. Previous clinical studies
have shown no differences in antiviral response between nevira-
pine-based and efavirenz-based ART.13,14 In contrast, other studies
have shown a trend towards a less favorable treatment outcome
for nevirapine-based ART when compared to efavirenz-based
ART.15,16 In a previous study we showed that 30% of patients who
received nevirapine and rifampin and 7% of patients who received
nevirapine without rifampin had nevirapine levels less than the
recommended level (<3.4 mg/l).17 In another previous study we
showed that a regimen of stavudine, lamivudine and nevirapine
provides a satisfactory durability and immunological response
over 144 weeks of follow-up.18 To date, long-term treatment
outcomes in the context of either HIV treatment or TB treatment in
these patients are unknown. Herein, we continue the clinical
follow-up of patients through 4 years, following on from our
previously described pharmacokinetic study.17
2. Materials and methods
The present study was designed as a 4-year prospective cohort
study involving 140 HIV-infected patients at the Bamrasnaradura
Infectious Diseases Institute, Ministry of Public Health, Nontha-
buri, Thailand. A primary objective was to assess virological and
immunological responses in co-infected HIV/TB patients who had
received a regimen of stavudine, lamivudine and nevirapine
400 mg/day for 4 years. A secondary objective was to assess the
treatment outcome of TB. There were 70 patients who had TB and
received rifampin (the TB group) and 70 patients who did not have
TB (the control group). Enrollment was from November 2004 to
March 2005. Inclusion criteria for both groups were as follows: (1)
HIV-infected and aged >15 years, (2) CD4 cell count of <350 cells/
mm3, and (3) participated and provided an informed consent form.
Additional inclusion criteria for the TB group were as follows: (4) a
diagnosis of active TB and (5) receiving a rifampin-containing anti-
TB regimen 1 month prior to enrollment. Exclusion criteria for
both groups were as follows: (1) prior receipt of any antiretroviral
drug, (2) being pregnant, (3) having aspartate aminotransferase
(AST) and alanine aminotransferase (ALT) levels >5 times the
upper limit of the normal range. An additional exclusion criterion
for the control group was receiving rifampin for any reason within
1 month prior to enrollment. The patients had follow-up visits
every 12 weeks after initiation of ART until 96 weeks, and every 24
weeks thereafter, at which time they were assessed clinically and
blood samples were taken.
The anti-TB regimen consisted of isoniazid, rifampin, etham-
butol and pyrazinamide administered in the ﬁrst 2 months,
followed by isoniazid and rifampin for the subsequent 4–7months.
The dosage of rifampin was 450 mg per day for patients with a
body weight <50 kg and 600 mg per day for patients with a body
weight 50 kg. TB treatment outcomes (cure, treatment complet-
ed, treatment failure) were evaluated using the World Health
Organization and the European Region of the International Union
Against Tuberculosis and Lung Disease (IUATLD) deﬁnitions.19
The dosage of stavudine was adjusted for body weight (i.e.,
stavudine 30 mg twice a day for body weight 60 kg and 40mg
twice a day for body weight >60 kg). The conventional dose of
nevirapine of 200 mg/day was given for the ﬁrst 2 weeks prior to
dose escalation to 400 mg/day. Stavudinewas switched to tenofovir
or zidovudine if stavudine-related adverse events developed,
including symptomatic hyperlactatemia, peripheral neuropathies,
and lipodystrophy. General characteristics (e.g., gender, age, body
weight, body mass index (BMI), previous opportunistic infections,
and site of TB infection) were recorded. Blood samples wereobtained to study CD4 cell counts by ﬂow cytometry andHIV-1 RNA
by polymerase chain reaction using Roche Amplicor1 version 1.5
(Roche Diagnostics, Branchburg, NJ, USA); the lower limit of HIV-1
RNAdetectionwas 50 copies/ml. Atweek8 andweek12of initiating
ART, blood samples were obtained from patients 12 h after they
were observed to have taken a dose of nevirapine to analyze plasma
nevirapine levels by high performance liquid chromatography
assay. Virological failure was deﬁned as either a rebound plasma
HIV-1 RNA of >1000 copies/ml after having a previously undetect-
able value or lack of achievement of <50 copies/ml at 24 weeks of
ART. Genotypic resistance testing (TRUGENE HIV-1 Genotyping
Assay, Visible Genetics Inc., Toronto, Canada) was performed after
the patient was documented with virological failure.
Mean ( standard deviation (SD)), median (interquartile range
(IQR)) and frequencies (%)were used to describe patient characteristics
in both groups. The Chi-square test was used to compare categorical
variables and the Mann–Whitney U-test to compare continuous
variables between the two groups. The proportions of patients with
plasma HIV-1 RNA <50 copies/ml after 4 years of ART were analyzed
according to intention-to-treat (ITT; all enrolledpatientswere included
in the analysis and if they discontinued ART for any reason they were
considered to be a treatment failure) andmodiﬁed ITT (i.e., all enrolled
patientswere included in the analysis but patients who switched from
stavudine were not considered to be treatment failure). If data on
plasma HIV-1 RNA levels were missing due to any reason they were
taken tobe>50 copies/ml. TheKaplan–Meier testwasused to estimate
the probability ofARTdiscontinuationdue toany reasonat 1, 2, 3, and4
years after ART initiation and the median time to ART discontinuation.
Patients who had been on a drug holiday of longer than 4 weeks were
considered tohavebeen lost to follow-upandwerecensoredat thedate
ofﬁrst loss to follow-upvisit. The log-rank testwasused to compare the
median time to ART discontinuation between the two groups.
Statistical calculations were performed using SPSS version 15.0 (SPSS
Inc., Chicago, IL, USA). A two-sided p-value of less than 0.05 was
considered statistically signiﬁcant. The institutional ethics committees
of the Bamrasnaradura InfectiousDiseases Institute and theMinistry of
Public Health approved the study.
3. Results
Of the 140 patients, the median (interquartile range (IQR)) CD4
count was 31 (14–79) cells/mm3 and median (IQR) plasma HIV-1
RNA was 5.6 (5.2–5.9) log copies/ml at baseline. Table 1
summarizes the baseline characteristics of the two groups. There
were no signiﬁcant differences in baseline characteristics (p> 0.05)
with the exceptions of baseline plasma HIV-1 RNA, which was
higher in the TB group (p = 0.014), and the proportions of females,
history ofmajor opportunistic infections, and older age, whichwere
greater in the control group (p < 0.05). In the TB group, 39 (55.7%)
patients were diagnosed with extrapulmonary/disseminated TB
and the rest were diagnosed with pulmonary TB. The median (IQR)
duration of TB treatment in the TB group was 7.1 (6.2–9.4) months.
The median (IQR) duration of concurrent administration of
nevirapine and rifampin was 5.4 (4.6–6.1) months. Thirty-eight
(54.3%) in the TB group and 36 (51.4%) in the control group
continued their initial regimen until the end of follow-up.
Figure 1 shows the ITT analysis at 4 years. The overall
percentage of patients who achieved plasma HIV-1 RNA <50
copies/mlwas 52.9% (37 of 70) in the TB group and 50% (35 of 70) in
the control group (p = 0.866; odds ratio (OR) 1.121, 95% conﬁdence
interval (CI) 0.578–2.176). By modiﬁed ITT analysis, there was also
no difference in terms of the proportion of patients with
undetectable plasma HIV-1 RNA between the two groups
(p = 0.862; OR 1.128, 95% CI 0.571–2.291). Among 17 patients in
the TB groupwho had trough plasma nevirapine levels of<3.4 mg/
l after 2 months of ART, as in our previous report,17 12 patients
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Figure 2. The probability of ART continuation in the two groups estimated by the
Kaplan–Meier method. Discontinuation of ART for any reason was considered to be
treatment failure.
Table 1
Comparison of baseline characteristics of the two study groups
Characteristics TB group
(n=70)
Control group (n=70) p-Value
Sex
Male 56 (80%) 39 (56%) 0.002
Female 14 (20%) 31 (44%)
Age (years), mean SD 34.46.2 37.28.7 0.028
Body weight (kg), mean SD 54.78.7 54.410.6 0.827
Body mass index (kg/m2), mean SD 19.72.4 20.53.4 0.097
History of previous major OIs 5 (7%) 14 (20%) 0.026
CD4 count (cells/mm3), median (IQR) 37 (17–77) 29 (8–112) 0.788
CD4%, median (IQR) 4 (2–8) 3 (1–6) 0.154
Plasma HIV-1 RNA (copies/ml), median (IQR) 505 000 (269 000–750 000) 291 000 (94 600–714 000) 0.014
Plasma HIV-1 RNA (log copies/ml), median (IQR) 5.7 (5.4–5.9) 5.6 (5.0–5.9) 0.004
ALP (mg/dl), median (IQR) 110 (75–154) 91 (70–128) 0.072
AST (U/l), median (IQR) 36 (27–60) 35 (26–47) 0.371
ALT (U/l), median (IQR) 27 (18–51) 32 (22–49) 0.169
Total bilirubin (mg/dl), median (IQR) 0.6 (0.5–0.8) 0.5 (0.4–0.7) 0.051
TB, tuberculosis; SD, standard deviation; OIs, opportunistic infections; IQR, interquartile range; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine
aminotransferase.
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for virological outcome. Results showed that one of them
developed virological rebound.
At 4 years, the median (IQR) CD4 count was 352 (271–580)
cells/mm3 in the TB group and 425 (308–615) cells/mm3 in the
control group (p = 0.238). The probability of ART continuation
estimated by the Kaplan–Meiermethod is shown in Figure 2. One-,
2-, 3-, and 4-year ART discontinuation rates due to any reasonwere
20%, 33%, 42%, and 49% in the TB group and 23%, 36%, 44%, and 51%
in the control group. The median time to ART discontinuation was
16.3 months in the TB group and 13.5 months in the control group
(log rank test, p = 0.651).
Table 2 shows the reasons for changing or discontinuing ART in
the two groups. There were no differences in term of the reasons
for drug discontinuation between the two groups (p = 0.642).
The distribution of thymidine analogue mutations in the two
groups is shown in Figure 3. Thymidine analogue mutations were
observed in six patients in the TB group and seven patients in the
control group. Overall, there were no differences in thymidine
analogue mutations and NNRTI resistance-associated mutations
(RAMs) between the two groups (p > 0.05). Nucleoside reverse
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Figure 1. Proportion of patients who achieved plasma HIV-1 RNA <50 copies/ml at
4 years in the two groups. *Intention-to-treat (ITT) analysis deﬁned as analysis that
included all enrolled patients; if patients discontinued ART for any reason, they
were considered to be treatment failures. **Modiﬁed intention-to-treat (modiﬁed
ITT) analysis deﬁned as analysis that included all enrolled patients; patients who
switched from stavudine due to its adverse events were not considered to be
treatment failures.transcriptase inhibitor (NRTI)-RAMs at positions 41, 67, 70, 215
and 219 were not found.
With regard to outcome in the 70 patients undergoing TB
treatment, 54 (77.1%) were cured/completed treatment, seven
(10%) defaulted, ﬁve (7.1%) died, two (2.9%) were transferred out,
and two (2.9%) had recurrence. Death was related to TB in one of
the patients who died.Table 2
Summary of reasons for changing or discontinuing ART, and treatment outcomes in
the two groups
Reason Group of patients
TB group (n=70) Control
group(n=70)
No ART discontinuation or switching
until the end of study
38 (54.3%) 36 (51.4%)
Change or discontinuation of ART 32 (45.7%) 34 (48.6%)
Lipodystrophy 7 (10%) 3 (4.3%)
Lost to follow-up 7 (10%) 8 (11.4%)
Virological rebound 6 (8.6%) 7 (10%)
Death 5 (7.1%) 4 (5.7%)
Drug allergy 3 (4.3%) 4 (5.7%)
Transferred out 2 (2.9%) 2 (2.9%)
Symptomatic hyperlactatemia
and/or neuropathy
1 (1.4%) 6 (8.6%)
Renal failure 1 (1.4%) 0 (0%)
TB, tuberculosis; ART, antiretroviral therapy.
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Figure 3. Summary of the prevalence of NRTI and NNRTI resistance-associated
mutations (RAMs) in the two groups.
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Rifampin can induce the activity of the cytochrome P450
enzymes in the liver,6 which results in a large reduction in the
plasma nevirapine level during concurrent use of the two drugs.
The extent of this reduction in nevirapine concentrations has been
shown to vary widely in previous studies.9,12,17,20 These data have
raised concerns of HIV treatment failure in co-infected patients on
this regimen. Sub-therapeutic plasma nevirapine levels have been
found in a proportion of study patients in India and Africa.20,21
However, previous studies in Thailand have demonstrated that up
to 70–86% of patients on concomitant nevirapine and rifampin had
plasma nevirapine levels above the minimum recommended
level.9,11 Although previous reports have suggested that the
majority of patients respond well to nevirapine-based ART in
the short-term, despite the occurrence of drug–drug interac-
tions,17 long-term clinical data are still lacking. Therefore long-
term clinical trials are required in order to determine whether or
not nevirapine-based ART used together with rifampin contributes
to a higher chance of treatment failure. Our previous results from
this cohort showed that the 60-week treatment response in terms
of both virological and immunological responses were not
different between those patients who received concurrent
nevirapine and rifampin and the control group that used
nevirapine without rifampin.22 The present study conﬁrms the
durability of this ART regimen for the long-term antiviral
treatment outcome at 4 years.
Another concern is that rifampin puts patients at risk of low
plasma nevirapine levels during the ﬁrst 2-week lead-in period,10
therefore encouraging the emergence of HIV resistant to nevira-
pine. This study shows that the proportion of patients who had
virological failure was not different between the two groups (8.6%
in the TB group vs. 10% in the control group). Although the
percentage of mutation at amino acid 103 appears to be different,
the difference in the absolute number of patients is very small.
However, further studies are required to determine if there is any
true difference in the presence of the K103Nmutation. Overall, the
HIV genotypic resistance pattern after virological rebound showed
no differences in NRTI- and NNRTI-RAMs between the groups,
including mutations at amino acid positions 65, 103, 181, 184, and
210. As expected, the most frequent NNRTI-RAM found in our
patients was Y181C. Nonetheless, a tendency of a higher
prevalence of NNRTI-RAMs after virological rebound was found
in those patients who had previously received rifampin than in
those who had never received rifampin, but this did not reach a
signiﬁcant level. A larger-scale study is needed to conﬁrm this
result.
With regard to treatment outcome in TB, results from the
present study show that 77.1% of patients were cured and
completed treatment. This proportion is considered to be a
favorable rate for ‘cured and completed treatment’ in patients
with a very advanced HIV infection. The recurrence rate after 4years of follow-up is very low, although we could not distinguish
the true relapse rate of TB from TB re-infection. Most relapses
usually occur within the ﬁrst 12 months after completion of
therapy. Almost three-quarters of patients received treatment of
longer than 6 months. All our patients received daily anti-TB
therapy for an intensive and continuation phase. A higher TB
relapse rate has been found in HIV-infected patients who received
intermittent therapy during the intensive phase.23 A recent meta-
analysis revealed that the factors ‘at least 8-month therapy with
rifamycin-containing regimen’, ‘initial daily dosing’ and ‘concomi-
tant use of ART’, were associated with a good outcome in TB
treatment.24
A number of limitations should be acknowledged. First, this
study was not designed to formally assess the present outcomes. It
was primarily designed to test for the equivalence of plasma
nevirapine level. Thus, a future larger study to conﬁrm these
results is still warranted. Second, a number of patients needed to
discontinue their antiretroviral treatments because of the long-
term metabolic complications of stavudine. However, this drug is
no longer used as the recommended NRTI drug in combination
with lamivudine due to its toxicity. Third, the optimal timing of
initiation of ART after starting TB treatment is not known.
Nonetheless, initiating ART while receiving TB treatment is
recommended for those patients who have a CD4 of <350 cells/
mm3 and is recommend in the HIV treatment guidelines.8
Ultimately, the CYP2B6 genotype is associated with altered activity
of hepatic enzymes in the liver and pharmacokinetics that may
inﬂuence the efﬁcacy of treatment, since rifampin causes a
decrease in nevirapine levels.21 Furthermore, the CYP2B6 gene is
highly polymorphic and is subject to pronounced inter-individual
variability in expression and activity.25 Given that genetic
determinants play a role in nevirapine pharmacokinetics, these
data may not be applicable to other ethnic groups. To the best of
our knowledge, this analysis is the ﬁrst clinical trial that has shown
the long-term outcome of concomitant HIV and TB treatment.
In summary, this study provides promising long-term clinical
data on nevirapine 400 mg/day-based ART in HIV-infected patients
diagnosed with active TB and receiving a rifampin-containing
regimen. Although efavirenz-based ART is a preferred regimen in
these patients, nevirapine may be a reasonable NNRTI option
combined with a backbone NRTI regimen for HIV-infected patients
who receive rifampin in many resource-limited countries, includ-
ing Thailand, and in those who cannot tolerate efavirenz and in
pregnant women in the ﬁrst trimester.
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